Swift Biosciences, Inc. today announced an Early Access Program for the Accel-NGS™ DNA Library Kit for Illumina Next Generation Sequencing (NGS) systems. This program follows the successful launch earlier this year of a similar product for use on Ion Torrent platforms. Swift’s new kit is designed to bring the same benefits – low input requirement, PCR-free capability and fast, easy workflow -to the Illumina platform. MiSeq and HiSeq users who register forthis Early Access Program will be able to experience the benefits of the Accel-NGS technology before the product is widely released and will receive introductory pricing.

With the Accel-NGS DNA Library Kit for Illumina, scientists can now produce high complexity,PCR-free libraries with as little as 250 ng of input DNA. Libraries at significantly lower input levels can be produced with a few cycles of PCR. Unlike other products, the Accel-NGS DNA Library Kit does not require intact double-stranded DNA, making it fully compatible with FFPE and damaged samples. Swift’s unique, sequential adaptation process also reduces adapter dimer formation to further maximize sequencing output.The Accel-NGS DNA Library Kit for Illumina protocol is fast, requiring approximately 90 minutes start-to-finish, and consists of a handful of easy steps, including bead-based separations that

eliminate the need for time-consuming, electrophoretic gel-based size selection. The streamlined Accel-NGS workflow is also suitable for automation.

To learn more about how Accel-NGS acceleratesNGS library preparation and the Early Access Program for the Illumina version of the kit, please visit www.swiftbiosci.com.

About Swift Biosciences

Swift Biosciences is a small, fast-moving company focused on developing innovative enabling technologies for genomics and personalized medicine. With the launch of its line of Accel-NGS products, Swift is now applying its unique technologies to the Next Generation Sequencing market. Swift is working diligently to improve NGS sample preparation, an area that has not

kept pace with the significant improvements made recently in NGS instrumentation and bioinformatics.

The company also has products for qPCR detection of mutations. Swift’s first products, launched in 2012, are based on myT® Primer technology which provides both high sensitivity and specificity in somatic mutation detection, making itideal for cancer research and diagnostic applications. To date, Swift has developed myT Primersfor common mutations in the BRAF and

KRAS genes, which demonstrate the superior performance capabilities of the technology.

Additional myT Primer reagents will be launched in the near future.

In December of 2012, Swift granted a non-exclusive license for myT Primers to an international diagnostics company. Swift will continue to develop myT Primers for RUO applications as well as license to other partners. To facilitate licensing by additional partners, Swift recently introduced a TechnologyAccess Programfor myT Primers.